Tokyo Tape
Sign in
← Takeda Pharmaceutical

Annual report

4502.TEDINET S100W07G
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥4.58T2024-04-01 → 2025-03-31Cons.Revenue IFRS
Revenue¥4.26T2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥4.03T2022-04-01 → 2023-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥3.57T2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥3.20T2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥342.6bn2024-04-01 → 2025-03-31Cons.Operating profit loss IFRS
Operating income¥214.1bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Profit before tax¥175.1bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS
Profit before tax¥52.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥375.1bn2022-04-01 → 2023-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥302.6bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥366.2bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥107.9bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥144.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥317.0bn2022-04-01 → 2023-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥230.1bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥376.0bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥108.1bn2024-04-01 → 2025-03-31Cons.Profit loss IFRS
Net income¥144.2bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥317.0bn2022-04-01 → 2023-03-31dCons.Profit loss IFRS (5-year summary)
Net income¥230.2bn2021-04-01 → 2022-03-31dCons.Profit loss IFRS (5-year summary)
Net income¥376.2bn2020-04-01 → 2021-03-31dCons.Profit loss IFRS (5-year summary)
Total assets¥14.25Tat 2025-03-31Cons.Assets IFRS
Total assets¥15.11Tat 2024-03-31Cons.Assets IFRS
Total assets¥13.96Tat 2023-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥13.18Tat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥12.91Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥7.31Tat 2025-03-31Cons.Liabilities IFRS
Total liabilities¥7.83Tat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥6.94Tat 2025-03-31Cons.Equity IFRS
Net assets / equity¥7.27Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥6.35Tat 2023-03-31dCons.Equity IFRS
Equity (owners)¥6.94Tat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥7.27Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Cash & equivalents¥385.1bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥457.8bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥533.5bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥849.7bnat 2022-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥966.2bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥1.06T2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥716.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥977.2bn2022-04-01 → 2023-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.12T2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.01T2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥367.1bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥463.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥607.1bn2022-04-01 → 2023-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥198.1bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥393.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥751.4bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥354.4bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥709.1bn2022-04-01 → 2023-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.07T2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.09T2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥68.362024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥92.092023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥204.292022-04-01 → 2023-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥147.142021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥240.722020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥67.232024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥91.162023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥201.942022-04-01 → 2023-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥145.872021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥238.962020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥4,407.01at 2025-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,635.56at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥4,087.49at 2023-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,665.61at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥3,308.93at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio48.7%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio48.1%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio45.5%at 2023-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio43.1%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio40.1%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE1.5%2024-04-01 → 2025-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE2.1%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE5.3%2022-04-01 → 2023-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE4.2%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE7.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees47,455at 2025-03-31Cons.Number of employees
Employees49,281at 2024-03-31Cons.Number of employees
Employees49,095at 2023-03-31dCons.Number of employees
Employees47,347at 2022-03-31dCons.Number of employees
Employees47,099at 2021-03-31dCons.Number of employees
Revenue¥580.4bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥595.6bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥632.1bn2022-04-01 → 2023-03-31dStandaloneNet sales (5-year summary)
Revenue¥764.3bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥602.6bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Operating income¥36.9bn2024-04-01 → 2025-03-31StandaloneOperating income
Operating income¥48.1bn2023-04-01 → 2024-03-31StandaloneOperating income
Ordinary income¥86.6bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥286.4bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥340.1bn2022-04-01 → 2023-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥550.9bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥50.0bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥199.3bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Profit before tax¥391.3bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Net income¥152.8bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥338.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥330.6bn2022-04-01 → 2023-03-31dStandaloneNet income loss (5-year summary)
Net income¥324.4bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥247.5bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Total assets¥9.49Tat 2025-03-31StandaloneAssets
Total assets¥9.76Tat 2024-03-31StandaloneAssets
Total assets¥9.41Tat 2023-03-31dStandaloneTotal assets (5-year summary)
Total assets¥9.64Tat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥10.86Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥5.50Tat 2025-03-31StandaloneLiabilities
Total liabilities¥5.67Tat 2024-03-31StandaloneLiabilities
Net assets / equity¥3.99Tat 2025-03-31StandaloneNet assets
Net assets / equity¥4.09Tat 2024-03-31StandaloneNet assets
Net assets / equity¥4.21Tat 2023-03-31dStandaloneNet assets
Net assets / equity¥4.29Tat 2022-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥4.43Tat 2021-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥169.6bnat 2025-03-31StandaloneCash and deposits
Cash and deposits¥130.9bnat 2024-03-31StandaloneCash and deposits
EPS (basic)¥96.792024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥216.62023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥213.062022-04-01 → 2023-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥207.52021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥158.452020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥96.782024-04-01 → 2025-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥216.562023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥213.052022-04-01 → 2023-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥207.52021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥158.442020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1962024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1882023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1802022-04-01 → 2023-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥1802020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥2,534.39at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,604.87at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥2,704.87at 2023-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,769.31at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥2,835.81at 2021-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio42.0%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio41.9%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio44.7%at 2023-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio44.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio40.8%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE3.8%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE8.2%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE7.8%2022-04-01 → 2023-03-31dStandaloneRate of return on equity (5-year summary)
ROE7.4%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE5.5%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued1,590,950,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,419,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,296,000at 2023-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,582,253,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued1,576,388,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees4,808at 2025-03-31StandaloneNumber of employees
Employees5,474at 2024-03-31StandaloneNumber of employees
Employees5,486at 2023-03-31dStandaloneNumber of employees
Employees5,149at 2022-03-31dStandaloneNumber of employees
Employees4,966at 2021-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 2
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2025-03-3147455 pure
Pharmaceutical Businessreportable segmentemployeesat 2025-03-314808 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,774
ItemContextValueUnit
Payout ratio (5-year summary)CurrentYearDuration_NonConsolidatedMember2.025
Number of employeesPrior4YearInstant_NonConsolidatedMember4966
Number of employeesPrior3YearInstant_NonConsolidatedMember5149
Number of employeesPrior2YearInstant_NonConsolidatedMember5486
Number of employeesPrior1YearInstant_NonConsolidatedMember5474
Number of employeesCurrentYearInstant_NonConsolidatedMember4808
Total shareholder returnPrior4YearInstant_NonConsolidatedMember1.259
Total shareholder returnPrior3YearInstant_NonConsolidatedMember1.166
Total shareholder returnPrior2YearInstant_NonConsolidatedMember1.478
Total shareholder returnPrior1YearInstant_NonConsolidatedMember1.485
Total shareholder returnCurrentYearInstant_NonConsolidatedMember1.613
Total return on share price indexPrior4YearInstant_NonConsolidatedMember1.421
Total return on share price indexPrior3YearInstant_NonConsolidatedMember1.450
Total return on share price indexPrior2YearInstant_NonConsolidatedMember1.534
Total return on share price indexPrior1YearInstant_NonConsolidatedMember2.168
Total return on share price indexCurrentYearInstant_NonConsolidatedMember2.134
Number of employeesCurrentYearInstant_jpcrp030000-asr_E00919-000PharmaceuticalBusinessReportableSegmentMember47455
Number of employeesCurrentYearInstant47455
Number of employeesCurrentYearInstant_NonConsolidatedMember4808
Average age years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember43.4
Average length of service years information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember14.4
Average annual salary information about reporting company information about employeesCurrentYearInstant_NonConsolidatedMember11038000JPY
Number of employeesCurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00919-000PharmaceuticalBusinessReportableSegmentMember4808
Number of employeesCurrentYearInstant_NonConsolidatedMember4808
Ratio of female employees in managerial positions metrics of reporting companyCurrentYearInstant_NonConsolidatedMember0.21
All employees calculated based on provisions of article714 item1 of ordinance for enforcement of act on childcare leave caregiver leave and other measures for the welfare of workers caring for children or other family members ratio of male employees taking childcare leave metrics of reporting companyCurrentYearInstant_NonConsolidatedMember0.815
All employees differences in wages between male and female employees metrics of reporting companyCurrentYearInstant_NonConsolidatedMember0.776
Regular employees differences in wages between male and female employees metrics of reporting companyCurrentYearInstant_NonConsolidatedMember0.803
Non regular employees differences in wages between male and female employees metrics of reporting companyCurrentYearInstant_NonConsolidatedMember0.633
Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissionsCurrentYearDuration_ConsolidatedAccountingGroupMember273000
Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissionsCurrentYearDuration_ConsolidatedAccountingGroupMember28000
Research and development expenses research and development activitiesCurrentYearDuration730200000000JPY
Capital expenditures overview of capital expenditures etcCurrentYearDuration2252000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember1590949609
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember1590961709
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant1590949609
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant1590961709
Number of shares constituting one unitCurrentYearInstant_OrdinaryShareMember100
Number of shareholders national and local governmentsCurrentYearInstant_OrdinaryShareMember1
Number of shareholders financial institutionsCurrentYearInstant_OrdinaryShareMember254
Number of shareholders financial service providersCurrentYearInstant_OrdinaryShareMember54
Number of shareholders other corporationsCurrentYearInstant_OrdinaryShareMember3459
Number of shareholders foreign investors other than individualsCurrentYearInstant_OrdinaryShareMember1086
Number of shareholders foreign individual investorsCurrentYearInstant_OrdinaryShareMember950
Number of shareholders individuals and othersCurrentYearInstant_OrdinaryShareMember562917
Number of shareholders totalCurrentYearInstant_OrdinaryShareMember568721
Number of shares held number of units national and local governmentsCurrentYearInstant_OrdinaryShareMember4
Number of shares held number of units financial institutionsCurrentYearInstant_OrdinaryShareMember4612461
Number of shares held number of units financial service providersCurrentYearInstant_OrdinaryShareMember1162403
Number of shares held number of units other corporationsCurrentYearInstant_OrdinaryShareMember492162

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2025-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass